Management of clinical stage T3/T4 bladder cancer: a review
World Journal of Urology · 29.09.2025 · 43 (1)
DOI: 10.1007/s00345-025-05960-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift World Journal of Urology, online erschienen am 29.09.2025. Verfasst von Domenique Escobar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Catherine and Joseph Aresty Department of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA , USA. Dome…. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Southern California.
Abstract (Originalsprache)
Introduction
Bladder cancer is a common malignancy in the United States and while the majority are non-muscle invasive at diagnosis, those with muscle-invasive and locally advanced disease can be challenging to manage. In addition, the prognosis is poorer in this group with high rates of recurrence following treatment. Clinical trials and advances in systemic therapy have helped to improve outcomes for these patients. Materials/methods Articles were chosen for inclusion based on expert knowledge of the literature and PubMed literature searches for the relevant areas, with a focus on clinical trials. Appropriate articles were selected for inclusion by reviewing article titles, abstracts and full texts.
Results
The standard of care for treatment of muscle invasive bladder cancer involves neoadjuvant chemotherapy followed by radical cystectomy. The NIAGARA trial recently changed the standard of care to include immunotherapy both in the neoadjuvant and adjuvant settings. Multiple clinical trials have assessed the potential benefit of adjuvant immunotherapy in patients with high-risk disease after radical cystectomy, leading to the approval of nivolumab in this setting. Improvements in staging and surveillance of these patients are necessary. The use of circulating tumor DNA and advances in imaging have also shown promise in prognostication and detection and monitoring of recurrence.
Conclusions
Locally advanced bladder cancer is a challenging condition to manage, and while advances have been made in systemic therapy and biomarkers such as circulating tumor DNA, further investigation is needed to continue to improve outcomes for this group of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Catherine and Joseph Aresty Department of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA , USA. Domenique.Escobar@med.usc.edu.
- USC Institute of Urology, 1441 Eastlake Ave, Suite 7416, Los Angeles, CA, 90089, USA. Domenique.Escobar@med.usc.edu.
- Catherine and Joseph Aresty Department of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA , USA.
Förderung
- University of Southern California
Zitieren
APA
Escobar, D., Zahir, M., Doshi, C., & Daneshmand, S. (2025). Management of clinical stage T3/T4 bladder cancer: a review. World Journal of Urology, 43(1). https://doi.org/10.1007/s00345-025-05960-3
Vancouver
Escobar D, Zahir M, Doshi C, Daneshmand S. Management of clinical stage T3/T4 bladder cancer: a review. World Journal of Urology. 2025;43(1). doi:10.1007/s00345-025-05960-3
BibTeX
@article{Escobar2025,
author = {Escobar, Domenique and Zahir, Mazyar and Doshi, Chirag and Daneshmand, Siamak},
title = {Management of clinical stage T3/T4 bladder cancer: a review},
journal = {World Journal of Urology},
year = {2025},
volume = {43},
number = {1},
doi = {10.1007/s00345-025-05960-3}
}
EUVIMED